Home Journals Books For Authors and Reviewers Online Submission News About Us Contact Us
Search
magazinelogo

International Journal of Clinical and Experimental Medicine Research

ISSN Print: 2575-7989 Downloads: 219103 Total View: 2502350
Frequency: quarterly ISSN Online: 2575-7970 CODEN: IJCEMH
Email: ijcemr@hillpublisher.com
Search articles within this journal Submit an article

Journal Menu

Volumes & Issues

Current Issue

Download PDF

How to cite this paper

1049

TOTAL VIEWS

More Articles

Article Open Access http://dx.doi.org/10.26855/ijcemr.2024.07.004

Efficacy and Safety of Spleen Aminopeptide Oral Lyophilized Powder in Patients with Frequent Acute Exacerbations of Bronchiectasis: A Randomized, Double-blind, Placebo-controlled, Single-center Clinical Trial

Miao Li, Lei Zhou, Yuanlin Song, Zhuozhe Li*, Dongni Hou*

Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai 200031, China.

*Corresponding author: Zhuozhe Li, Dongni Hou

Published: August 16,2024

Abstract

Background: Bronchiectasis is a common chronic inflammatory and infectious disease of the airway, which has a high prevalence and frequent acute exacerbations. The treatment approaches for bronchiectasis include mucolytic agents and an immune enhancement strategy, but the latter lacks evidence from randomized controlled trials (RCTs) supporting their efficacy. Spleen Aminopeptide Oral Lyophilized Powder (SAOLP) is a bidirectional immune modulator, mainly composed of a complex of peptides and nucleotides, with an average molecular weight of around 3500. It contains various amino acids and immune regulatory factors, which can trigger and enhance cellular immune function, and promote the immune balance of the body. Methods: A randomized, double-blind, placebo-controlled, single-center clinical trial of SAOLP was conducted in patients with non-cystic fibrosis bronchiectasis. The participants received placebo or SAOLP 4mg/d for 3 months and were followed up for 6 months. The primary outcome was a number of acute exacerbations in 6 months. The secondary outcome was the presence of respiratory symptoms at 6 months. Adverse effects were also recorded and analyzed. Results: SAOLP decreased the number of acute exacerbations (corrected χ2 test, p = 0.038) and alleviated respiratory symptoms (p = 0.0141) in non-cystic fibrosis bronchiectasis compared with placebo. There was no significant increase in adverse events in the SAOLP group (p > 0.9999) compared with the placebo group. Conclusion: Usage of SAOLP for 3 months may have potential benefits for non-cystic fibrosis bronchiectasis in reducing acute exacerbations and improve respiratory symptoms. More large and multi-center studies are needed to provide more evidence for its clinical use and determine the duration of treatment.

References

[1] Rth L. On mediate auscultation, or a treatise on the diagnosis of diseases of the lungs and heart. Paris: J.-A. Broson et J.-S Chaude; 1819.

[2] Keistinen T, Saynajakangas O, Tuuponen T, et al. Bronchiectasis: an orphan disease with a poorly-understood prognosis. Eur Respir J., 1997, 10:2784-2787. doi:10.1183/09031936.97.10122784.

[3] Chalmers JD, Chang AB, Chotirmall SH, et al. Bronchiectasis. Nat Rev Dis Primers, 2018, 4:45. doi:10.1038/s41572-018-0042-3.

[4] Qi Q, Wang W, Li T, et al. Aetiology and clinical characteristics of patients with bronchiectasis in a Chinese Han population: A prospective study. Respirology, 2015, 20:917-924. doi:10.1111/resp.12574.

[5] Pj. C. Inflammation: a two-edged sword--the model of bronchiectasis. Eur J Respir Dis Suppl. 1986:147:146-115. 

[6] Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. Eur Respir J., 2015, 45:1446-1462.

doi:10.1183/09031936.00119114.

[7] Hill AT, Haworth CS, Aliberti S, et al. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur Respir J., 2017, 49. doi:10.1183/13993003.00051-2017.

[8] Ai L, Liu J, Jiang Y, et al. Specific PCR method for detection of species origin in biochemical drugs via primers for the ATPase 8 gene by electrophoresis. Mikrochim Acta., 2019, 186:634. doi:10.1007/s00604-019-3738-5.

[9] Shen Xf ZA, Huang Q. An analysis of spleen aminopeptide oral lyophilized powder in the treatment of children after tonsillectomy. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi Chinese. 2017 Nov. 5, 31:1690-1692. doi: 10.13201/j.issn.1001-1781.2017.21.017.

[10] Wang W Y-XL, Min Hu. Efficacy of spleen aminopeptide combined with vitamin A and E in the treatment of children with recurrent respiratory tract infection and its immune function. Clin Misdiagn Misther., 2019, 32:21-24. 

[11] Boying Du GJ, Liu C, Weiwei Ma, Qin X, Suwen Xu. Observation of the curative effect of Yupingfeng granule and spleen aminopeptide in the children with pneumonia and syndrome of lung-spleen deficiency in recovery stage. Modern J Integr Trad Chin Western Med., 2017, 26:3883-3885. 

[12] Liang Xu M-XZ, Bang-Wei Cao. Therapeutic efficacy of oral lyophilized powder splenic aminopeptide combined with platinum-containing chemotherapy in patients with gastrointestinal tumors. Chin J Clin Oncol Rehabil., 2019, 26:1043-1047. 

[13] Wu Y, Dong X, Wu R, et al. Efficacy and safety of spleen aminopeptide oral lyophilized powder in ameliorating liver injury in infants and children with human cytomegalovirus infection: a single-center study in China. Transl Pediatr., 2021, 10:136-145. doi:10.21037/tp-20-173.

[14] Wang J, Ma X, Shang K, et al. Safety and efficacy of spleen aminopeptide oral lyophilized powder for improving quality of life and immune response in patients with advanced breast cancer: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Anticancer Drugs., 2021, 32:1067-1075. doi:10.1097/CAD.0000000000001109.

[15] Tan Tj LG, Liao Jy, Zeng Gq, Gan L, Shui-Lan Lu, Et Al. The effect of spleen aminopeptide on treatment and prevention of pediatric repeated respiratory infection and its influence on T lymphocyte subset. Med Recapitulate, 2015, 21:2257-2258. 

[16] Qing Pp LR, Lv D. Curative effect of spleen aminopeptide oral lyophilized powder combined with recombinant human interferon α-2b ointment on verruca plana and its influence on T-lymphocyte subsets, IL-2, IL- 4, INF-γ in adolescent patients. Pi Fu Xing Bing Xue Za Zhi, 2016, 38:1-4. 

[17] Polverino E, Goeminne PC, Mcdonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J., 2017, 50. doi:10.1183/13993003.00629-2017.

[18] Finch S, Laska IF, Abo-Leyah H, et al. Validation of the COPD Assessment Test (CAT) as an Outcome Measure in Bronchiectasis. Chest, 2020, 157:815-823. doi:10.1016/j.chest.2019.10.030.

[19] J C Bestall 1 EaP, R Garrod, R Garnham, P W Jones, J a Wedzicha, Expand A. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax, 1999 Jul; 54(7):581-6. doi: 10.1136/thx.54.7.581. 

[20] Martinez-Garcia MA, De Gracia J, Vendrell Relat M, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. European Respiratory Journal, 2013, 43:1357-1367. doi:10.1183/09031936.00026313.

[21] Bernd Löwe 1 KK, Wolfgang Herzog, Kerstin Gräfe. Measuring depression outcome with a brief self-report instrument: sensitivity to change of the Patient Health Questionnaire (PHQ-9). J Affect Disord., 2004, 2004 Jul; 81(1):61-6. doi: 10.1016/S0165-0327(03)00198-8. 

[22] Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med., 2014, 189:576-585. doi:10.1164/rccm.201309-1575OC.

[23] Qing Pp LR, Lv D. Curative effect of spleen aminopeptide oral lyophilized powder combined with recombinant human interferon α-2b ointment on verruca plana and its influence on T-lymphocyte subsets, IL-2, IL-4, INF-α in adolescent patients. Pi Fu Xing Bing Xue Za Zhi, 2016; 38:1-4. 

[24] Luo Xf XH, Cai J. The effect of spleen aminopeptide combined with ganciclovir in the treatment of children cytomegalovirus infection. Zhong Guo Lin Chuang He Li Yong Yao Za Zhi, 2016; 9:36-7. 

[25] Choi H, Chalmers JD. Bronchiectasis exacerbation: a narrative review of causes, risk factors, management and prevention. Annals of Translational Medicine, 2023, 11:25-25. doi:10.21037/atm-22-3437.

[26] Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA, 2013; 309(12):1251-1259. doi:10.1001/jama.2013.1937.

[27] Vrančić M, Banjanac M, Nujić K, et al. Azithromycin distinctively modulates classical activation of human monocytes in vitro. Br J Pharmacol., 2012; 165(5):1348-1360. doi:10.1111/j.1476-5381.2011.01576.x.

[28] Fouka E, Lamprianidou E, Arvanitidis K, et al. Low-dose clarithromycin therapy modulates Th17 response in non-cystic fibrosis bronchiectasis patients. Lung, 2014; 192(6):849-855. doi:10.1007/s00408-014-9619-0.

How to cite this paper

Efficacy and Safety of Spleen Aminopeptide Oral Lyophilized Powder in Patients with Frequent Acute Exacerbations of Bronchiectasis: A Randomized, Double-blind, Placebo-controlled, Single-center Clinical Trial

How to cite this paper: Miao Li, Lei Zhou, Yuanlin Song, Zhuozhe Li, Dongni Hou. (2024) Efficacy and Safety of Spleen Aminopeptide Oral Lyophilized Powder in Patients with Frequent Acute Exacerbations of Bronchiectasis: A Randomized, Double-blind, Placebo-controlled, Single-center Clinical Trial. International Journal of Clinical and Experimental Medicine Research, 8(3), 390-398.

DOI: http://dx.doi.org/10.26855/ijcemr.2024.07.004

Home　|　Journals　|　Books　|　For Authors and Reviewers　|　Online Submission　|　Contact Us　|　About Us

Copyright © 2023 Hill Publishing Group Inc. All Rights Reserved.